ChinaFile Recommends
11.02.16Drug Giant Faced a Reckoning as China Took Aim at Bribery
New York Times
China sought to make an example of GlaxoSmithKline in a case that involved bribery of doctors and investigators and ended with guilty pleas and record penalties
ChinaFile Recommends
07.14.14GSK China’s Private-Eyes Indicted in Shanghai for Illegal Probe
Xinhua
Peter William Humphrey, a 58-year-old Brit, and his wife Yu Ying Zeng, a 61-year old American, were arrested last August. Theirs is the first indictment Chinese prosecutors have announced on foreigners for illegal investigation.
ChinaFile Recommends
06.29.14Undercover Sex Tape Deepens GSK’s China Scandal
Telegraph
GlaxoSmithKline has confirmed the existence of a sex tape featuring Mark Reilly, the former manager at the centre of the company's corruption investigation.
ChinaFile Recommends
05.14.14Chinese Police Charge British Former Head of GSK in China With Bribery
Reuters
The case is the biggest corruption scandal to hit a foreign company in China since the Rio Tinto affair in 2009, which resulted in four executives, including an Australian, being jailed for between 7-14 years.
ChinaFile Recommends
09.05.13Bribery in G.S.K. China Was Coordinated at Company Level
Reuters
A Chinese police investigation into drugmaker GlaxoSmithKline has discovered that alleged bribery of doctors in China was coordinated by the British company and was not the work of individual employees, state...
ChinaFile Recommends
07.31.13Corporate Sleuths On Edge After China Detains Foreign Consultants
Reuters
The detention by Chinese authorities of a British corporate investigator and his American wife in the wake of a corruption probe into pharmaceutical giant GlaxoSmithKline has had a chilling effect on other risk consultants working...
Conversation
07.30.13Is Business in China Getting Riskier, Or Are Multinationals Taking More Risks?
Arthur Kroeber:The environment for foreign companies in China has been getting steadily tougher since 2006, when the nation came to the end of a five-year schedule of market-opening measures it pledged as the price of admission to the World Trade...
ChinaFile Recommends
07.25.13Glaxo Chief Executive Addresses China Inquiry
New York Times
Andrew Witty, chief executive of the drug maker GlaxoSmithKline, said on Wednesday that the accusations of bribery and corruption against his company in China were “deeply disappointing.” But he said that Glaxo’s headquarters in London had not been...
ChinaFile Recommends
07.25.13More Foreign Pharmaceutical Firms Could Be Probed In China
Reuters
China's official news agency hinted that more foreign pharmaceutical firms could soon be implicated in a corruption scandal sweeping the industry, in the wake of bribery accusations against British drug maker GlaxoSmithKline. ...
ChinaFile Recommends
07.23.13Drug Research in China Falls Under a Cloud
New York Times
A leaked document related to the recent G.S.K. scandal underscores the problems that can arise when major drug companies export their scientific development to emerging markets like China.
ChinaFile Recommends
07.22.13Glaxo Says Executives May Have Broken Chinese Law
New York Times
The British pharmaceutical giant GlaxoSmithKline said Monday that some of its executives might have broken the law in China, the company’s strongest statement yet on a bribery and corruption scandal that has engulfed its China...
ChinaFile Recommends
07.18.13China Bars GlaxoSmithKline Executive From Leaving During a Bribery Inquiry
New York Times
The effort to restrict Steve Nechelput’s travel came as the government ramped up an unusually bold anti-corruption campaign against GlaxoSmithKline, which is one of the world’s biggest drug makers.